Indeed there is no need for interjoint injections as via the sub-cat route of administration our Magic gets into the said joints anyway and the amount of action in my view is enough/efficacious. I suspect that this pathway (in vivo via subQ) would have benefits over and above a direct injection method. Plus the fact that a direct injection into the joint would be more painful compared to under the skin (subQ).
So there is not much point, few if any advantages and possible disadvantages. In fact direct injection may be less efficacious as the outside of the joint may not get the same level of benefit...it is the helping of the membrane for example, on the outside that could add to the benefit (facilitation of nutrient supply to within the joint). This of course depends on the mode of action which will be studied in detail later on.
I haven't come across any research of a study of Pentosan directly like that, there are plenty that use stem cells or PRP and others though directly into the joint. Certainly in my opinion there could be room and merit for a dosing of iPPS first and then stem cell treatment at a slightly later interval but this is a long way off and would require comprehensive studies before they roll that out at scale (I believe there are some few cases where this might have been tested in a handful of patients)...I suspect initially at least (first x number of years) iPPS will be widely adopted and the benefits will be quite stand alone (spec. comments)...
I have read a few times that there is a VAST difference between PPS and iPPS in terms of where it goes in the body and how it acts. There is more to this story for sure.
DYOR as always
PAR Price at posting:
$2.64 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)